Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
- PMID: 33005446
- PMCID: PMC7508219
- DOI: 10.1155/2020/4231841
Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
Abstract
Purpose: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves.
Results: This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1-48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2-148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%.
Conclusions: Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases.
Copyright © 2020 Duangnate Rojanaporn et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest pertaining to the publication of this article.
Figures


Similar articles
-
Management outcome(s) in eyes with retinoblastoma previously inadequately treated with systemic chemotherapy alone without focal therapy.Oman J Ophthalmol. 2017 May-Aug;10(2):70-75. doi: 10.4103/ojo.OJO_225_2015. Oman J Ophthalmol. 2017. PMID: 28757689 Free PMC article.
-
Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.J Pediatr Ophthalmol Strabismus. 2016 Sep 1;53(5):275-84. doi: 10.3928/01913913-20160719-04. Epub 2016 Aug 4. J Pediatr Ophthalmol Strabismus. 2016. PMID: 27486728
-
A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma: Part II: Treatment Success and Globe Salvage.Ophthalmology. 2020 Dec;127(12):1733-1746. doi: 10.1016/j.ophtha.2020.05.051. Epub 2020 Jun 8. Ophthalmology. 2020. PMID: 32526306
-
Aqueous seeding in intraocular retinoblastoma: A review.Clin Exp Ophthalmol. 2021 Aug;49(6):606-614. doi: 10.1111/ceo.13964. Epub 2021 Jul 9. Clin Exp Ophthalmol. 2021. PMID: 34185374 Review.
-
Modern treatment of retinoblastoma: A 2020 review.Indian J Ophthalmol. 2020 Nov;68(11):2356-2365. doi: 10.4103/ijo.IJO_721_20. Indian J Ophthalmol. 2020. PMID: 33120616 Free PMC article. Review.
Cited by
-
Correlation between clinical presentations, radiological findings and high risk histopathological features of primary enucleated eyes with advanced retinoblastoma at Queen Sirikit National Institute of Child Health: 5 years result.PLoS One. 2022 Jul 20;17(7):e0270362. doi: 10.1371/journal.pone.0270362. eCollection 2022. PLoS One. 2022. PMID: 35857757 Free PMC article.
-
Clinicoepidemiological Profile and Treatment Outcomes in Children with Retinoblastoma: Experience from a Cancer Care Center in Northeast India.South Asian J Cancer. 2022 Feb 27;11(3):269-273. doi: 10.1055/s-0041-1740326. eCollection 2022 Jul. South Asian J Cancer. 2022. PMID: 36588614 Free PMC article.
-
Hope level and associated factors among parents of retinoblastoma patients during COVID-19 pandemic: a cross-sectional study.BMC Psychiatry. 2021 Aug 6;21(1):391. doi: 10.1186/s12888-021-03401-0. BMC Psychiatry. 2021. PMID: 34362326 Free PMC article.
-
Challenges and Outcomes of Retinoblastoma Treatment in Ethiopia A Case of Jimma University Medical Center, Southwest Ethiopia.Ethiop J Health Sci. 2025 Mar;35(2):96-100. doi: 10.4314/ejhs.v35i2.5. Ethiop J Health Sci. 2025. PMID: 40511273 Free PMC article.
-
The Impact of Tumor Laterality (Unilateral vs. Bilateral) on Presentation and Management Outcome in Patients with Retinoblastoma.J Clin Med. 2024 Apr 8;13(7):2146. doi: 10.3390/jcm13072146. J Clin Med. 2024. PMID: 38610910 Free PMC article.
References
-
- Wiangnon S., Veerakul G., Nuchprayoon I., et al. Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pacific Journal of Cancer Prevention: APJCP. 2011;12(9):2215–2220. - PubMed
LinkOut - more resources
Full Text Sources